BMS Reports Positive Opdivo Results in CheckMate-648 Trial

Bristol Myers Squibb says there were positive topline results in the Phase 3 CheckMate-648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma. A company statement says that in the study Opdivo demonstrated a statistically significant and clinically meaningful benefit for the primary and secondary endpoints of overall survival in patients whose tumors express PD-L1 and in the all-randomized PD-L1.

Opdivo plus Yervoy met its primary and secondary endpoints by demonstrating statistically significant and clinically meaningful improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. Opdivo plus Yervoy did not meet its other primary endpoint of progression-free survival in patients whose tumors express PD-L1, the statement says.